96 Tests PN: B111434

Components:

45x Ab-conjugated beads (S4P12 - human MPO Ab-bead). PN: B111434A. One vial containing 100 µL of anti-human MPO conjugated to AimPlex Bead S4P12.

25x Biotin-detection Ab (human MPO Biotin-dAb). PN: B111434B. One vial containing 100 µL of biotinylated anti-human MPO.

Lyophilized Standard Mix-Human Group 2 Panel B, 10-Plex. PN: HG20010. One vial containing lyophilized recombinant human IL-17F, IL-20, IL-21, IL-28A, IL-29, IL-33, M-CSF, MPO, TSLP, and VEGF-A. Note: If multiple analyte kits on the above target list are ordered as a panel, only one vial of standard mix is supplied for those analyte kits. 

Application: Optimal antibody pair and antigen standard for assaying human MPO.  Can be multiplexed with other analytes in Human Group 2.  To be used in conjunction with the AimPlex NR Basic Kit (PN: P100001) and a diluent kit. Refer to the AimPlex Multiplex Immunoassay User Manual and kit inserts for the assay procedure.

Storage:  2-8 C in the dark.

Important: Sodium azide forms explosive compounds with heavy metals. These products contain <0.05% (w/w) azide which with repeated contact with lead and copper commonly found in plumbing drains may result in the buildup of shock sensitive compounds. Dispose in accordance with regulations from your institute.

For Research Use Only.  Not for use in diagnostic procedures.

Assay Specifications:

  • Sample types: Cell culture supernatant, serum, plasma, bodily fluid and tissue/cell lysate

  • Sensitivity (LOD): < 10 pg/mL

  • Quantitation range:

  • LLOQ: < 20 pg/mL

  • ULOQ: > 5,000 pg/mL

  • Standard dose recovery: 70-130%

  • Intra-assay CV: < 10%

  • Inter-assay CV: < 20%

  • Cross-reactivity of analytes in Human Group 2: Negligible

  • Sample volume: 15 µL/test

Description:

Myeloperoxidase (Accession P05164), formerly known as verdoperoxidase is a peroxidase enzyme of the XPO subfamily. It is expressed from neutrophils and is involved in killing off bacteria, fungi, tumor cells, among other extracellular responses. Currently, MPO is the only human enzyme known to be able to degrade carbon nanotubes, which may cause an unwanted buildup of nanotubes in tissues after a medicine targeted delivery.  MPO expression has been linked to inflammation and oxidative stress which are correlated with atherosclerosis and an increased risk of cardiovascular disease, and myeloperoxidase deficiency, which predisposes to immune deficiency.

References:

  1. Kagan VE, et al. Carbon nanotubes degraded by neutrophil myeloperoxidase induce less pulmonary inflammation. Nat Nanotechol. 2010; 5(5): 254-9. Doi: 10.1038/nnano.2010.44.

  2. Kutter D, et al. Consequences of total and subtotal myeloperoxidase deficiency: risk or benefit? Acta Haematol. 2000; 104(1): 10-15. Doi: 10.1159/000041062.

  3. Schindhelm RK, van der Zwan LP, Teerlink T, Scheffer PG. Myeloperoxidase: A Useful Biomarker for Cardiovascular Disease Risk Stratification? Clinical Chemistry. 2009; 55(8). Doi: 10.1373/clinchem.2009.126029.

  4. Tobler A, Koeffler HP. (1991). Myeloperoxidase: Localization, Structure, and Function. In: Harris J.R. (eds) Blood Cell Biochemistry Volume 3. Blood Cell Biochemistry , vol 3. Springer, Boston, MA.